Oncode Institute
In research, Oncode Institute stands highest in Life Sciences (#368 of 7,800 worldwide), Medicine (#1,084 of 10,443 worldwide) and Health Sciences (#1,589 of 11,982 worldwide), 2022–2025. Relative to its size it is most specialised in Oncology, Cancer Research and Immunology — Oncology is 14.8× its share of world research.
- World rank, 2022–2025
- #1,177 of 28,054 · #1,424 all time
- Rank in Netherlands
- #19 of 237
- Research works
- 2.5k ▲ 144% vs 2013–17
- Citations
- 171k 69.2 per fractional work
- Top-10% rate
- 35.0% record average 16.5%
- Open access
- 63% world 28%
What is Oncode Institute known for in research?
The fields where it stands highest, 2022–2025, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works | All time |
|---|---|---|---|---|---|
| Life SciencesDomain | #368 of 7,800 | 37.7% | 252 | #499 | |
| MedicineField | #1,084 of 10,443 | 33.4% | 282 | #1047 | |
| Health SciencesDomain | #1,589 of 11,982 | 33.3% | 286 | #1381 | |
| Biochemistry, Genetics and Molecular BiologyField | #477 of 3,579 | 35.6% | 194 | #570 | |
| OncologySubfield | #120 of 772 | 37.5% | 98 | #118 | |
| Molecular BiologySubfield | #383 of 2,175 | 36.8% | 123 | #408 |
Each strip is that field’s whole ranked pool, with the notch where Oncode Institute sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
Which of those standings moved
The same fields on both windows: where it stood over the whole record, and where it stands in 2022–2025. The distance is the story, and it is the one thing the two rank columns above cannot show.
- Life Sciences#499 #368
- Medicine#1,047 #1,084
- Health Sciences#1,381 #1,589
- Biochemistry, Genetics and Molecular Biology#570 #477
- Oncology#118 #120
- Molecular Biology#408 #383
A dot further right is a better standing. Fields it was not ranked in over the whole record are left out.
What does Oncode Institute specialise in?
Where its research is concentrated relative to its size: Oncology takes 14.8× the share of its output that it takes of world research.
- OncologySubfield · 97.9 works15×
- Cancer ResearchSubfield · 27.1 works11×
- ImmunologySubfield · 42.7 works11×
- Immunology and MicrobiologyField · 44.5 works7.5×
- Molecular BiologySubfield · 123.4 works7.0×
Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 7.5×. Every wedge is a field page.
- Immunology and Microbiology 7.5×
- Biochemistry, Genetics and Molecular Biology 6.2×
- Medicine 2.5×
- Pharmacology, Toxicology and Pharmaceutics 1.4×
- Veterinary 0.7×
- Neuroscience 0.6×
- Chemistry 0.6×
- Mathematics 0.5×
- Physics and Astronomy 0.3×
- Nursing 0.3×
- Computer Science 0.3×
- Economics, Econometrics and Finance 0.2×
- Agricultural and Biological Sciences 0.2×
- Health Professions 0.2×
- Engineering 0.1×
- Materials Science 0.1×
- Dentistry 0.1×
- Psychology 0.1×
- Environmental Science 0.0×
- Decision Sciences 0.0×
- Earth and Planetary Sciences 0.0×
- Energy 0.0×
- Arts and Humanities 0.0×
- Social Sciences 0.0×
- Business, Management and Accounting 0.0×
Which keywords describe research at Oncode Institute?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Immunotherapy, Chemotherapy, Cancer, Tumor Microenvironment, Cancer Therapy, Cancer Immunotherapy, Immunity and Targeted Therapy.
- Epithelial-Mesenchymal Transition
- Transcription Factors
- Drug Resistance
- Tumor Regression
- Cancer Genomics
- Cell-Free DNA
- Lymphoma
- Tumor Antigen
- Breast Cancer
- Antigen Presentation
- Radiotherapy
- Survival Analysis
- Neoadjuvant Therapy
- Clinical Practice Guidelines
- PD-1 and PD-L1
- Gene Expression
- Immunity
- Cancer Therapy
- Tumor Microenvironment
- Cancer
- Immunotherapy
- Chemotherapy
- Inflammation
- Cancer Immunotherapy
- Targeted Therapy
- Immune Checkpoint Blockade
- Genomic Instability
- Innate Immunity
- Precision Medicine
- Chromatin
- Prognostic Factors
- Clinical Trials
- Dendritic Cells
- Vaccine Adjuvants
- Molecular Characterization
- Metastasis
- Mutational Signatures
- Gene Regulation
- Cancer Risk
- Epigenetics
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Immunotherapy44▲ 11×19 topics
- Cancer44▲ 5.6×40 topics
- Chemotherapy43▲ 10×23 topics
- Tumor Microenvironment37▲ 14×8 topics
- Inflammation30▲ 2.4×61 topics
- Cancer Therapy29▲ 8.6×15 topics
- Cancer Immunotherapy28▲ 31×3 topics
- Immunity25▲ 11×9 topics
- Targeted Therapy24▲ 18×4 topics
- Gene Expression24▲ 6.6×16 topics
- Immune Checkpoint Blockade23▲ 35×1 topic
- PD-1 and PD-L123▲ 35×1 topic
- Genomic Instability22▲ 34×3 topics
- Clinical Practice Guidelines21▲ 6.6×12 topics
- Innate Immunity20▲ 11×10 topics
- Neoadjuvant Therapy20▲ 14×5 topics
- Precision Medicine20▲ 7.2×7 topics
- Survival Analysis20▲ 12×7 topics
- Chromatin19▲ 69×2 topics
- Radiotherapy18▲ 7.9×13 topics
- Prognostic Factors17▲ 6.8×14 topics
- Antigen Presentation17▲ 33×2 topics
- Clinical Trials17▲ 4.2×10 topics
- Breast Cancer15▲ 11×10 topics
- Dendritic Cells15▲ 29×2 topics
- Tumor Antigen15▲ 42×1 topic
- Vaccine Adjuvants15▲ 42×1 topic
- Lymphoma14▲ 15×4 topics
- Molecular Characterization14▲ 14×4 topics
- Cell-Free DNA14▲ 25×2 topics
- Metastasis14▲ 7.0×12 topics
- Cancer Genomics14▲ 32×1 topic
- Mutational Signatures14▲ 32×1 topic
- Tumor Regression14▲ 21×2 topics
- Gene Regulation13▲ 25×4 topics
- Drug Resistance13▲ 7.8×6 topics
- Cancer Risk13▲ 9.8×6 topics
- Transcription Factors12▲ 18×4 topics
- Epigenetics12▲ 49×2 topics
- Epithelial-Mesenchymal Transition12▲ 22×3 topics
Which research topics does Oncode Institute publish most on?
By volume in 2022–2025: Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Cancer Genomics and Diagnostics and Cancer Cells and Metastasis.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Cancer Immunotherapy and Biomarkers Oncology 23 works
- 2 Immunotherapy and Immune Responses Immunology 15 works
- 3 Cancer Genomics and Diagnostics Cancer Research 14 works
- 4 Cancer Cells and Metastasis Oncology 12 works
- 5 Genomics and Chromatin Dynamics Molecular Biology 11 works
- 6 CAR-T cell therapy research Oncology 11 works
- 7 CRISPR and Genetic Engineering Molecular Biology 8 works
- 8 Radiomics and Machine Learning in Medical Imaging Radiology, Nuclear Medicine and Imaging 8 works
- 9 Immune Cell Function and Interaction Immunology 8 works
- 10 DNA Repair Mechanisms Molecular Biology 8 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Oncode Institute's research output changed?
Output in 2018–2022 was 144% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Utrecht
- Utrecht University
- University Medical Center Utrecht
- Rutgers Sexual and Reproductive Health and Rights
- Huisarts en Wetenschap
- Wilhelmina Children's Hospital
- University of Applied Sciences Utrecht
- Geneeskundige en Gezondheidsdienst
- University of Humanistic Studies
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.